Company intelligence / Profile preview

Neuraltus Pharmaceuticals

San Bruno, California, United States6sense.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

Neuraltus’ lead candidate, NP001, was a novel small molecule immune regulator targeting inflammation in ALS. Initial Phase II data suggested possible benefit in patients with elevated systemic inflammation biomarkers, but a larger confirmatory Phase IIb trial failed to meet primary and secondary endpoints. The company ceased operations following this failure.[5][6]

Therapeutic areas: OncologyImmunologyRare DiseasesNeurology
Modalities: Small moleculesImmune regulators
Industry: Biotech

Drug pipeline

2 assets

NP002

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborated with global ALS specialists and patient advocacy organizations during development; no major pharma partnerships disclosed.[2]

Beyond the preview

Go deeper on Neuraltus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraltus Pharmaceuticals.

Explore the full profile